We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
Cap. Flow
+$284M
Cap. Flow %
244.1%
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$4.59M
2
BIIB icon
Biogen
BIIB
+$3.56M
3
CALM icon
Cal-Maine
CALM
+$2.79M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
5
AAPL icon
Apple
AAPL
+$2.33M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$4.11M
2
GILD icon
Gilead Sciences
GILD
+$2M
3
IBM icon
IBM
IBM
+$1.48M
4
CMG icon
Chipotle Mexican Grill
CMG
+$930K
5
EXPE icon
Expedia Group
EXPE
+$914K

Sector Composition

Rank Sector Weight
1 Healthcare 41.4%
2 Technology 6.27%
3 Consumer Staples 4.14%
4 Consumer Discretionary 2.26%
5 Materials 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HD icon
226
PUT
Home Depot
HD
$338B
$31K 0.03%
+20,800
New +$2.75M
HRTX icon
227
CALL
Heron Therapeutics
HRTX
$89.1M
$30K 0.03%
20,200
-42,900
-68% -$838K
LUMN icon
228
CALL
Lumen
LUMN
$6.47B
$30K 0.03%
+15,400
New +$449K
TNXP icon
229
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
A icon
230
CALL
Agilent Technologies
A
$37.1B
$29K 0.02%
+82,500
New +$3.56M
TAP icon
231
CALL
Molson Coors Class B
TAP
$7.68B
$29K 0.02%
5,600
-23,500
-81% -$2.31M
OPK icon
232
Opko Health
OPK
$899M
$28K 0.02%
+3,000
New +$30.5K
IDCC icon
233
PUT
InterDigital
IDCC
$6.73B
$27K 0.02%
+9,800
New +$554K
CMRX
234
CALL
DELISTED
Chimerix, Inc.
CMRX
$27K 0.02%
199,900
+54,900
+38% +$271K
ABBV icon
235
CALL
AbbVie
ABBV
$450B
$26K 0.02%
38,844
-100
-0.3% -$6.09K
KLAC icon
236
PUT
KLA
KLAC
$278B
$26K 0.02%
+65,000
New +$466K
CAB
237
CALL
DELISTED
Cabela's Inc
CAB
$26K 0.02%
+16,100
New +$801K
ARMH
238
CALL
DELISTED
ARM HOLDINGS PLC ADS
ARMH
$26K 0.02%
+10,000
New +$422K
CCEP icon
239
CALL
Coca-Cola Europacific Partners
CCEP
$46.5B
$25K 0.02%
+19,400
New +$914K
ICPT
240
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$25K 0.02%
20,200
-15,300
-43% -$2.23M
HLF icon
241
CALL
Herbalife
HLF
$1.24B
$24K 0.02%
13,200
-200
-1% -$5.99K
RGLS
242
PUT
DELISTED
Regulus Therapeutics
RGLS
$24K 0.02%
42
– –
T icon
243
PUT
AT&T
T
$152B
$24K 0.02%
186,816
+15,358
+9% +$457K
WDC icon
244
CALL
Western Digital
WDC
$164B
$24K 0.02%
5,980
-1,826
-23% -$60.1K
CAB
245
PUT
DELISTED
Cabela's Inc
CAB
$24K 0.02%
+15,000
New +$747K
RLYP
246
PUT
DELISTED
RELYPSA INC COM
RLYP
$24K 0.02%
+30,000
New +$527K
FXI icon
247
PUT
iShares China Large-Cap ETF
FXI
$4.6B
$23K 0.02%
+37,900
New +$1.26M
RPTP
248
CALL
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$23K 0.02%
+42,100
New +$216K
IRBT
249
PUT
DELISTED
iRobot
IRBT
$22K 0.02%
+6,500
New +$238K
VEEV icon
250
CALL
Veeva Systems
VEEV
$31.7B
$22K 0.02%
+20,000
New +$594K
8 9
10
11 12

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q2 2016 Portfolio in Review

As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.

  • FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
  • FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
  • FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
  • FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
  • FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
  • FT Options opened 171 new positions and closed 122 in Q2 2016.
  • FT Options's portfolio value rose 22% quarter-over-quarter to $116M.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.